$AVNS

Egbuonu-Davis Lisa sold (to issuer) $345K of AVNS

Egbuonu-Davis Lisa sold (to issuer) 13,811 shares of AVANOS MEDICAL, INC. (AVNS) at $25.00 ($0.35M total) on 2026-07-27.

Original reporting
SEC EDGAR · Egbuonu-Davis Lisa
Published Jul 28, 2026, 9:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVNS
Neutral
high confidence
Mentioned
$AVNS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVNSNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (13,811 shares) but does not include new guidance, trial results, contracts, or regulatory actions.

02

Market read

Traders may note insider selling, but the filing lacks new fundamental information and is typically low-impact for valuation.

03

What to watch

No 10b5-1 plan is indicated, but the transaction code D and the post-transaction holdings of 0 shares suggest a planned or mechanical event rather than a new thesis.

Relevance 4/10Novelty 3/10Timing: after-hours SEC Form 4 filed 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for AVANOS MEDICAL, INC.

Company-level read

Ticker impact

$AVNSNeutralHigh confidence
Context

Director Egbuonu-Davis Lisa sold 13,811 shares to the issuer for $345,275 at $25.00/share, leaving 0 shares after the transaction.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment/positioning rather than new company information.

Evidence & confidence

The filing is a Form 4 insider transaction, but it does not disclose new operational, financial, or regulatory developments beyond the sale mechanics and resulting holdings.

Market effects

No clear sector read-through from a single director sale to the issuer.

None.

None.

Counterpoint

A sale to the issuer can be administrative (for example, buyback participation or liquidity) and may not reflect bearish expectations.

Key entities

  • AVANOS MEDICAL, INC.

    Company whose director insider transaction is disclosed on Form 4.

  • Egbuonu-Davis Lisa

    Director who sold shares to the issuer under transaction code D.

Related articles

$AVNSLow

AVANOS MEDICAL, INC. (AVNS): Completion of Acquisition or Disposition of Assets

AVANOS MEDICAL, INC. (AVNS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 4 avnsform8k_07272026xex101.htm EX-10.1 Document Execution Version CREDIT AGREEMENT dated as of July 27, 2026 among A-AV MERGERSUB, INC., as the Initial Borrower, AVANOS MEDICAL, INC., as the Borrower Representative, A-AV ACQUIRECO, INC., as a Borrower, A-AV INTERMEDIATEC